Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Pancreatic Carcinoma: early-phase trial registry
A small indexed set (7 trials) with no open enrollment listed right now.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · none currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Pancreatic Carcinoma: 7 US clinical trials tracked, none currently recruiting.
Recurrent Pancreatic Carcinoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition recurrent-pancreatic-carcinoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 7 | RANK #2497 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Pancreatic Carcinoma has no open enrollment in this registry pull (7 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Pancreatic Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Pancreatic Carcinoma is recruiting below its size-band peers.
0 of 7 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Pancreatic Carcinoma research.
National Cancer Institute (NCI) accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Pancreatic Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.
-
Recurrent Pancreatic Carcinoma research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
7 total, page 1 of 1
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT02890355
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
NCT03257761
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00878163
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
NCT03073785
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01660971
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
NCT02451553
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
NCT02620865
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Pancreatic Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Pancreatic Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Pancreatic Carcinoma page
7 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Pancreatic Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Recurrent Pancreatic Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Pancreatic Carcinoma condition card totals 7 registered trials; most-linked intervention Gemcitabine Hydrochloride; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.